Marten Heeringa
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial.
Journal: Pediatrics
Published: July 20, 2022
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
Journal: The New England journal of medicine
Published: October 13, 2021
Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization Assays.
Journal: Journal of clinical microbiology
Published: April 14, 2020
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).
Journal: Investigational new drugs
Published: May 13, 2014
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.
Journal: Investigational new drugs
Published: February 04, 2014
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
Journal: Biopharmaceutics & drug disposition
Published: March 15, 2013
Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?
Journal: Biomarkers in medicine
Published: December 12, 2012
Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: November 22, 2012
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
Journal: Clinical pharmacology in drug development
Published: October 29, 2012
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin.
Journal: European journal of drug metabolism and pharmacokinetics
Published: September 14, 2012
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
Journal: British journal of clinical pharmacology
Published: May 31, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026